R&D channel feed

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Yesterday

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

Yesterday

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

2 days ago
Cell/Gene Tx
In Focus

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

2 days ago

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

3 days ago
Pharma
Manufacturing

Theri­va’s on­colyt­ic virus suc­ceeds in pan­cre­at­ic can­cer study, but stock falls

3 days ago

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

3 days ago
Cell/Gene Tx

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

3 days ago

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

4 days ago

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

4 days ago

Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta

4 days ago

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

5 days ago

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

5 days ago
Pharma
FDA+

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

5 days ago
AI

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

5 days ago
Cell/Gene Tx

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

6 days ago
China
Cell/Gene Tx

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

6 days ago

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Last week
Cell/Gene Tx

FDA with­draws two fi­nal guid­ances, pulls com­pli­ance dead­lines for bone al­lo­graft mak­ers

Last week
Pharma
FDA+

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

Last week
Cell/Gene Tx

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for Wern­er drug

Last week

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

Last week
Manufacturing

Mod­er­na, fac­ing rev­enue miss­es and po­lit­i­cal head­winds, dis­ap­points Wall Street

Last week
Pharma

CROs raise the alarm as clients de­lay R&D plans over fund­ing, tar­iff wor­ries

Last week
Outsourcing
1234 Next page Last page
A service from the Financial Times